Redeye updates on Invisio following the company’s Q3-results which saw stronger topline than expecte...
Redeye provides an update subsequently Gapwaves Q3 2023 report.
NOI and Rec PTP +2% and -2%, respectively, vs ABGSCe Limited net letting, flat occupancy, strong mar...
Redeye sees a Q3 report that roughly matched our expectations and was in line with Management’s guid...
Redeye updates its view on Artificial Solutions (AS) on the back of its Q3 2023 report.
Redeye thinks the Q3 report was good, and in line with what the company had previously indicated.
Redeye comments on Alligator’s Q3 report. The OPTIMIZE-1 topline readout will be a major catalyst an...
Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and s...
CapMan's Q3 fell short of Refinitiv consensus expectations, we believe partly owing to lower carry b...
Q3: Large volume-driven beat Pulp prices on the rise Fair value range: SEK 9-16/sh Q3: Figures well...
Agilyx released several operational and organizational announcements this evening which positions th...
A poor quarter, but Q4e should be better Adj. EBITA down 4-5% for '23e-'25e 14x '24e EV/EBITA, 19% '...
Challenging market environment currently Adj. numbers show signs of progress No help from the constr...
4.5% organic sales growth y-o-y EBITA margin flat y-o-y adj.
ARR increased by 7% q-o-q and 55% y-o-y Sales 5% below, and costs 5% higher vs.
Acquires IPO Prämien Services for EUR 7.8m Implied multiple of 16x-4x EBITDA on '22/23-'21/22 Could ...
Redeye updates its view of IRLAB following the Q3 report and largely reiterate our previous view.
Adj. EBITA SEK 193m (-4% vs. ABGSCe, -3% vs. cons) We expect cons.
Tangiamo Touch Technology meddelade den 26 oktober 2023 att bolaget har lanserat en helt ny MultiPLA...
Early Signs of Improved Momentum in Private.
